Here is the reformatted article.
Liquid Biopsies Show Promise for Colorectal Cancer Detection and Monitoring
A comprehensive narrative review published in Clinica Chimica Acta explores the potential of liquid biomarkers for transforming the early detection, diagnosis, and treatment monitoring of colorectal cancer (CRC). The study analyzed literature from PubMed/NCBI, Scopus, and Web of Science, covering research published between 2010 and 2025.
The review focuses on a range of biomarker types, including circulating tumor DNA (ctDNA), microRNAs (miRNAs), and markers derived from genomics, epigenomics, the gut microbiome, metabolomics, and proteomics.
Non-invasive liquid biomarkers could address critical limitations of traditional methods like colonoscopy, which is invasive, and fecal tests, which often suffer from poor patient adherence.
The Critical Window for Early Detection
Detectable in either blood or stool samples, these biomarkers offer a less daunting alternative for patients. This is crucial given the stark survival statistics for colorectal cancer:
- Early-stage localized CRC: Survival rates exceed 90% .
- Metastatic disease: Survival rates drop below 15% .
The authors conclude that integrating these biomarkers into screening programs could significantly enhance compliance, enable earlier intervention, and ultimately reduce CRC-related morbidity and mortality.
A Global Health Challenge
This research arrives at a critical time. Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. According to the Global Cancer Observatory, 2022 saw approximately:
- 1.9 million new cases
- 904,000 deaths
The global disease burden is projected to increase, driven by factors such as an aging population, urbanization, rising obesity rates, and dietary changes.
Toward Precision Medicine
The review strongly emphasizes that multi-omics technologies—the analysis of multiple biological data sets—are key to advancing precision medicine in CRC management. By providing a more complete molecular picture of the disease, these tools could lead to more personalized treatment strategies and better patient outcomes.